Cannabis Sativa Inc (OTCMKTS:CBDS) is a low-priced trading equity that has grabbed hold of the attention of traders during the stock’s recent bounce. The company is at an extremely interesting point: last week, they put out an announcement that the new Ibudtender app will be ready for beta testing “this coming week” – which means now. According to the release, “This new app will hold the highest health and safety standards for consumers to date.”
The stock is up 30% since mid-December, but down over 25% off its January highs. So, the action has been wild and wooly, to sum things up. What’s more, the company has witnessed a pop in interest, as transaction volume levels have recently pushed 22% beyond what we have been seeing over the larger time frame. This is particularly important given the stock’s extremely small trading float of 7.2M shares. One is wise to respect the dynamic this may create — a mechanically driven price squeeze can result from this type of mix of small float and ramping attention from traders. Since we last covered the name, the stock has moved -11.4% lower.
Cannabis Sativa Inc (OTCMKTS:CBDS) is a diversified play in the cannabis space. It’s most recent strategic footprint expansion came into place with its grab of iBudtender, Inc., a Colorado corporation that currently offers information and reviews of dispensaries, cannabis businesses, strains, edibles, concentrates and products.
In addition, the Company also offers herbal based line of products through its Wild Earth subsidiary, including Go Deep, a deep penetrating healing salve that reduces pain and inflammation when massaged into muscles, ligaments, tendons, and joints; Go Deep EXTRA, a deep penetrating pain relief ointment for use in mitigating migraine and sinus headaches; Face Garden, an antioxidant and moisturizing cream for the face; Body Garden, a moisturizing body lotion; and Lip Garden, an emollient balm.
But perhaps most importantly, the Company also directly engages in the research, development, and licensing of natural cannabis products comprising cannabis formulations, edibles, topicals, strains, recipes, and delivery systems.
CBDS plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula. Cannabis Sativa Inc is also developing a third strain of cannabis plant named CT22.
Find out when $CBDS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, the company is finally ready to roll out the iBudtender app for a beta testing process. As investors find ways to get their hands on it, the stock may start to reflect that assessment.
“The Ibudtender team has been working hard to complete what will be the most sophisticated app in the space”, said David Tobias, President of Cannabis Sativa. “The beta test will give the technology a chance to perform, interact with users, get analyzed and perfected, and a final release to follow quickly.”
Th release goes on to note that “Ibudtender is accepting applications from select consumers for this project. Ibudtender is also accepting a limited number of dispensaries, delivery services and manufacturers to test its new state of the art business software.”
For a little background, “Ibudtender is a comprehensive medical cannabis resource. Patients can find cannabis medication based on their needs and preferences and medicate safely knowing exactly what is in their medicine and how to use it properly and safely. Our one-of-a-kind system connects patients, dispensaries, businesses and providers together not just socially, but commercially and personally as well. The same product a provider adds to our system can be found and shared by patients, doctors, advocates and investors as well as added to dispensary menus creating a cycle of knowledge and awareness. We want to help make the medical cannabis industry a safer one for all to benefit from and grow upon.”
At this time, carrying a capital value in the market of $116M, Cannabis Sativa has virtually no cash on the books, which stands against about $336K in total current liabilities. One should also note that debt has been growing over recent quarters. CBDS is pulling in trailing 12-month revenues of $76K. In addition, the company is seeing top line growth, with y/y quarterly revenues growing at 5.2%. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $CBDS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!